StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

Innoviva pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Innoviva's pe ratio was 4.6× on Nov 11, 2026, against 29.2× a year earlier. Over the last 5 years it ranged from 3.5× to 29.2×, with a median of 6.3×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.6×−24.1
2025Jan 31, 202528.7×+2.0
2024Dec 31, 202426.7×+4.1
2023Dec 29, 202322.6×+18.4
2022Dec 30, 20224.2×−1.4
2021Dec 31, 20215.5×−0.8
2020Dec 31, 20206.3×+2.1
2019Dec 31, 20194.2×−6.1
2018Dec 31, 201810.3×−5.8
2017Dec 29, 201716.1×−15.3
2016Dec 30, 201631.5×–

More Innoviva figures

See a number that looks wrong?